<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liashkovich I</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</funding><funding>Ministry of Education and Science of the Russian Federation</funding><pagination>e10425</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10354767</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(4)</volume><pubmed_abstract>Clathrin-mediated endocytosis (CME) is an essential cell physiological process of broad biomedical relevance. Since the recent introduction of Pitstop-2 as a potent CME inhibitor, we and others have reported on substantial clathrin-independent inhibitory effects. Herein, we developed and experimentally validated a novel fluorescent derivative of Pitstop-2, termed RVD-127, to clarify Pitstop-2 diverse effects. Using RVD-127, we were able to trace additional protein targets of Pitstop-2. Besides inhibiting CME, Pitstop-2 and RVD-127 proved to directly and reversibly bind to at least two members of the small GTPase superfamily Ran and Rac1 with particularly high efficacy. Binding locks the GTPases in a guanosine diphosphate (GDP)-like conformation disabling their interaction with their downst</pubmed_abstract><journal>Bioengineering &amp; translational medicine</journal><pubmed_title>Pitstop-2 and its novel derivative RVD-127 disrupt global cell dynamics and nuclear pores integrity by direct interaction with small GTPases.</pubmed_title><pmcid>PMC10354767</pmcid><funding_grant_id>Finance Code 001</funding_grant_id><funding_grant_id>SH 167/6‐1</funding_grant_id><funding_grant_id>075‐15‐2022‐264</funding_grant_id><funding_grant_id>LI 2157/3‐1</funding_grant_id><funding_grant_id>SH 167/6‐2</funding_grant_id><funding_grant_id>SH 167/9‐1</funding_grant_id><pubmed_authors>Gorelkin PV</pubmed_authors><pubmed_authors>Kolmogorov V</pubmed_authors><pubmed_authors>Stefanello ST</pubmed_authors><pubmed_authors>Bulk E</pubmed_authors><pubmed_authors>Kouzel IU</pubmed_authors><pubmed_authors>Haufe G</pubmed_authors><pubmed_authors>Liashkovich I</pubmed_authors><pubmed_authors>Mizdal CR</pubmed_authors><pubmed_authors>Dulebo A</pubmed_authors><pubmed_authors>Erofeev A</pubmed_authors><pubmed_authors>Shahin V</pubmed_authors><pubmed_authors>Vidyadharan R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pitstop-2 and its novel derivative RVD-127 disrupt global cell dynamics and nuclear pores integrity by direct interaction with small GTPases.</name><description>Clathrin-mediated endocytosis (CME) is an essential cell physiological process of broad biomedical relevance. Since the recent introduction of Pitstop-2 as a potent CME inhibitor, we and others have reported on substantial clathrin-independent inhibitory effects. Herein, we developed and experimentally validated a novel fluorescent derivative of Pitstop-2, termed RVD-127, to clarify Pitstop-2 diverse effects. Using RVD-127, we were able to trace additional protein targets of Pitstop-2. Besides inhibiting CME, Pitstop-2 and RVD-127 proved to directly and reversibly bind to at least two members of the small GTPase superfamily Ran and Rac1 with particularly high efficacy. Binding locks the GTPases in a guanosine diphosphate (GDP)-like conformation disabling their interaction with their downst</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-06-02T12:03:34.307Z</modification><creation>2026-04-18T03:11:19.173Z</creation></dates><accession>S-EPMC10354767</accession><cross_references><pubmed>37476059</pubmed><doi>10.1002/btm2.10425</doi></cross_references></HashMap>